2016 April | The Journal of Targeted Therapies in Cancer

Markers of Excellence

July 13, 2016

Clinical Articles

The word "marker" is defined, in medical terms, as "something that serves to identify, predict, or characterize." A variation on this word, known as a biological marker, or biomarker (defined as a measurable indicator of a biological condition) takes this concept one step further.

Cost of Biologics Therapy Soars Above Other Cancer Expenses

July 08, 2016

Clinical Articles

Biologics therapy spending soared several hundred percent from 2004 to 2014; but despite rising treatment costs in general, oncology spending kept pace with spending for all categories of medical care, according to a report on Medicare and commercial data from the Community Oncology Alliance.

From the Editor: Exciting Advancements in Therapeutic Regimens

July 08, 2016

Clinical Articles

Advances in the treatment of cancer have been possible due to the use of agents that target genomic mutations involving oncogenic signaling and immune regulatory pathways. These advances have resulted in major paradigm shifts in our clinical approach to the patient with metastatic cancer.

Next Generation Diagnostics for Immuno-Oncology

July 07, 2016

Clinical Articles

Unlike traditional diagnostics that measure the presence, absence, or altered levels of a single analyte, immuno-oncology diagnostics seek to coalesce large amounts of immunological and tumor information into "signatures" that can be used to guide patient care.

The Importance of Biomarkers for Cancer Immunotherapy

July 07, 2016

Clinical Articles

Immunotherapy for cancer has been studied in the laboratory and in early-phase trials for decades. Larger trials were not often successful enough, though in the last five years, a revolution has centered around the clinical success of checkpoint blockade with CTLA-4 and PD-1 antibodies.

Integrating Immunotherapy With Chemoradiation in the Treatment of Head and Neck Cancer

July 06, 2016

Clinical Articles

Squamous cell carcinoma of the head and neck (SCCHN) is an immunosuppressive disease, as its patients often demonstrate immune dysregulation that correlates with poorer outcomes. Trials are underway combining chemoradiotherapy with immune checkpoint inhibitors.